<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="192730">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583297</url>
  </required_header>
  <id_info>
    <org_study_id>CDx_000001</org_study_id>
    <nct_id>NCT00583297</nct_id>
  </id_info>
  <brief_title>Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial</brief_title>
  <official_title>Identifying Genetic Markers That Predict Microvolt T-wave Alternans Status and Arrhythmia Risk in Patients With Ischemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioDx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ABCD clinical study (ClinicalTrials.gov Identifier NCT00187291) was designed to
      determine if a T-Wave Alternans (TWA) test is equivalent to an Electrophysiology Study (EPS)
      in predicting life-threatening heart rhythms in patients with ischemic heart disease, left
      ventricular dysfunction, and non-sustained tachycardia. The purpose of the ABCD Genetic
      sub-study is to identify genetic markers that predict TWA status and arrhythmia risk in this
      same population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotype and Pre-implant T-wave alternans status.</measure>
    <time_frame>two years as per original ABCD trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotype and occurrence of appropriate cardioversion for ventricular tachycardia or ventricular fibrillation</measure>
    <time_frame>two years per original ABCD trial</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Heart Failure</condition>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>ABCD Subjects</arm_group_label>
    <description>The cohort will consist of original subjects of the ABCD trial who consent to participate in the genetic sub-study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>No Intervention.</description>
    <arm_group_label>ABCD Subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and saliva.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for the ABCD genetic sub-study includes all living individuals
        currently enrolled in the ABCD trial (total study enrollment=629; 566 analyzed in the
        trial) Participants of the ABCD trial underwent TWA and EPS testing to determine their
        risk for ventricular arrhythmia and most have received an implantable cardioverter
        defibrillator (ICD). The ABCD trial collected extensive longitudinal clinical data
        including medical and medication histories, incidence of ventricular arrhythmias,
        defibrillator shocks, other cardiovascular events, and mortality.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects previously enrolled in the ABCD trial sponsored by St. Jude Medical
        (ClinicalTrials.gov Identifier NCT00187291)

          -  patients with ischemic heart disease

          -  left ventricular ejection fraction (LVEF) &lt; 40%

          -  non-sustained ventricular tachycardia

        Exclusion Criteria:

        Individuals who were not previously enrolled in the ABCD trial are not eligible for this
        genetic sub-study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy J Sehnert, MD</last_name>
    <role>Study Director</role>
    <affiliation>CardioDx, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Kaufman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wilson LD, Wan X, Rosenbaum DS. Cellular alternans: a mechanism linking calcium cycling proteins to cardiac arrhythmogenesis. Ann N Y Acad Sci. 2006 Oct;1080:216-34. Review.</citation>
    <PMID>17132786</PMID>
  </reference>
  <reference>
    <citation>Bloomfield DM, Bigger JT, Steinman RC, Namerow PB, Parides MK, Curtis AB, Kaufman ES, Davidenko JM, Shinn TS, Fontaine JM. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol. 2006 Jan 17;47(2):456-63. Epub 2005 Dec 15.</citation>
    <PMID>16412877</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 6, 2011</lastchanged_date>
  <firstreceived_date>December 20, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Amy Sehnert, MD, Director, Clinical R&amp;D</name_title>
    <organization>CardioDx, Inc.</organization>
  </responsible_party>
  <keyword>Arrhythmia</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>T wave Alternans (TWA)</keyword>
  <keyword>Implanted Cardioverter Defibrillator(ICD)</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Molecular Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
